background
destruct
architectur
subsequ
function
integr
lung
follow
pulmonari
viral
infect
attribut
extent
pathogen
replic
hostgener
inflamm
associ
recruit
immun
respons
presenc
antigen
dispar
pulmonari
virus
emerg
novel
virus
assur
recurr
lung
damag
infect
resolut
primari
viral
infect
thu
need
develop
safe
broad
spectrum
immunoprophylact
strategi
capabl
enhanc
protect
immun
respons
lung
limit
immunemedi
lung
damag
immunoprophylact
strategi
describ
util
protein
cage
nanoparticl
pcn
significantli
acceler
clearanc
divers
respiratori
virus
primari
infect
also
result
host
immun
respons
caus
less
lung
damag
methodologyprincip
find
mice
pretreat
pcn
independ
specif
viral
antigen
protect
subleth
lethal
dose
two
differ
influenza
virus
mouseadapt
sarscoronaviru
mous
pneumoviru
treatment
pcn
significantli
increas
surviv
mark
enhanc
viral
clearanc
acceler
induct
viralspecif
antibodi
product
signific
decreas
morbid
lung
damag
enhanc
protect
appear
depend
upon
prior
develop
induc
bronchusassoci
lymphoid
tissu
ibalt
lung
respons
pcn
treatment
mediat
cell
b
cell
depend
mechan
conclusionssignific
immunoprophylact
strategi
describ
util
infectionindepend
induct
natur
occur
ibalt
prior
infect
pulmonari
viral
pathogen
strategi
nonspecif
enhanc
primari
immun
respiratori
virus
restrict
antigen
specif
inher
typic
vaccin
strategi
pcn
treatment
asymptomat
applic
importantli
amelior
damag
inflamm
normal
associ
recruit
immun
respons
lung
citat
wiley
ja
richert
le
swain
sd
harmsen
barnard
dl
et
al
induc
bronchusassoci
lymphoid
tissu
elicit
protein
cage
nanoparticl
enhanc
protect
mice
divers
respiratori
virus
plo
one
current
immunoprophylact
strategi
gener
broad
spectrum
protect
divers
respiratori
viral
pathogen
convent
strategi
protect
respiratori
pathogen
reli
vaccin
individu
viru
strain
use
drug
base
therapi
howev
efficaci
immunoprophylact
strategi
often
significantli
limit
either
difficulti
engin
effect
vaccin
respiratori
virus
respiratori
syncyti
viru
evas
acquir
immun
result
antigen
variat
circul
respiratori
viral
pathogen
swine
influenza
pandem
addit
convent
strategi
gener
applic
newli
emerg
virus
sar
outbreak
sinc
sudden
appear
allow
time
develop
vaccin
sinc
mani
pathogen
either
directli
infect
mucos
epithelium
enter
host
penetr
mucos
surfac
induct
effect
pathogenspecif
immun
local
mucos
site
becom
desir
object
novel
vaccin
strategi
mucos
oppos
system
vaccin
often
efficaci
mucos
pathogen
due
abil
induc
secretori
iga
despit
advantag
vaccin
mucos
epitheli
surfac
especi
lung
pose
signific
safeti
concern
due
fragil
tissu
likelihood
trigger
unwant
pulmonari
inflamm
consequ
critic
develop
novel
method
pulmonari
immun
focu
gener
effect
mucos
immun
also
amelior
concomit
inflammatori
respons
thu
new
immunoprophylact
strategi
facilit
local
gener
protect
immun
broad
spectrum
lung
pathogen
abl
diminish
detriment
inflammatori
sequela
associ
onset
primari
adapt
andor
innat
immun
respons
site
infect
would
highli
advantag
therapi
caus
format
induc
bronchusassoci
lymphoid
tissu
ibalt
may
provid
altern
immunoprophylact
approach
broad
spectrum
viral
protect
lung
although
ibalt
develop
known
occur
associ
pulmonari
immun
respons
signific
role
ibalt
resolut
infect
recent
investig
notabl
role
adapt
immun
influenza
viru
infect
remark
ibalt
replac
function
spleen
secondari
lymphoid
tissu
primari
adapt
immun
respons
also
support
mainten
reexpans
adapt
immun
memori
respons
follow
influenza
viru
infect
associ
ibalt
lung
patholog
autoimmun
diseas
necess
infect
induct
divert
attent
immunoprophylact
potenti
ibalt
demonstr
ibalt
induc
asymptomat
without
infect
ensu
patholog
preexist
ibalt
enhanc
acceler
primari
adapt
like
innat
immun
respons
respiratori
virus
host
protein
cage
nanoparticl
pcn
util
deriv
small
heatshock
protein
shsp
hyperthermophil
archaeon
methanococcu
jannaschii
unrel
class
heatshock
protein
hsp
noninfecti
pcn
compris
ident
subunit
spontan
selfassembl
hollow
spheric
protein
cage
nm
diamet
figur
interestingli
pulmonari
instil
pcn
induc
ibalt
develop
within
lung
parenchyma
figur
wherea
treatment
pb
vehicl
control
induc
detect
ibalt
format
figur
pcninduc
ibalt
structur
form
submu
cosa
adjac
blood
vessel
lymph
duct
associ
bifurc
conduct
airway
level
termin
bronchiol
pcninduc
ibalt
structur
contain
b
cell
cell
follicular
dendrit
cell
figur
cell
data
shown
similar
ibalt
structur
induc
influenza
infect
seen
noninduc
secondari
lymphoid
tissu
mice
treat
pcn
protect
spectrum
respiratori
viral
pathogen
mice
treat
pcn
protect
subsequ
primari
influenza
viru
infect
character
significantli
greater
reduct
viral
burden
day
postinfect
figur
absenc
weight
loss
figur
lung
damag
indic
decreas
level
albumin
figur
lactat
dehydrogenas
ldh
figur
recov
bronchoalveolar
lavag
fluid
balf
although
also
observ
enhanc
protect
ug
pcn
administ
prior
influenza
infect
subsequ
found
dose
ugdos
pcn
optim
achiev
acceler
viral
clearanc
reduc
morbid
addit
acceler
viral
clearanc
reduc
morbid
level
observ
resolut
influenza
infect
pcntreat
mice
found
dose
depend
figur
determin
extent
pcn
treatment
could
provid
similar
level
enhanc
protect
respiratori
virus
infect
pcnor
pbstreat
mice
murineadapt
sarscoronaviru
figur
notabl
pcntreat
mice
surviv
infect
minim
weight
loss
wherea
pbstreat
mice
rapidli
lost
weight
die
day
postinfect
figur
similarli
found
pcntreatment
enhanc
protect
mice
infect
either
altern
influenza
viru
strain
figur
infect
pneumoviru
mice
pvm
figur
c
infect
mice
pvm
result
viral
lung
infect
similar
rsv
infect
human
test
whether
phenomenon
common
pcn
construct
balbc
mice
also
treat
human
hchain
ferritin
hfn
protein
cage
challeng
influenza
viru
control
group
mice
also
treat
bovin
serum
albumin
bsa
although
reduct
viral
burden
signific
mice
treat
hfn
treat
pcn
reduct
viral
burden
fold
greater
pcn
treat
mice
figur
viral
burden
significantli
differ
bsatreat
pbstreat
mice
neither
hfn
bsa
treatment
protect
mice
weight
loss
follow
infect
figur
b
thu
evid
overal
effect
pcn
enhanc
immun
gener
featur
pcn
architectur
small
heatshock
pcn
appear
uniqu
well
suit
facilit
enhanc
protect
broad
spectrum
respiratori
virus
format
ibalt
structur
pcntreat
mice
figur
increas
cellular
content
recov
balf
pcntreat
mice
prior
infect
tabl
indic
abil
pcn
act
pulmonari
immunostimulatori
agent
spite
pcndriven
immunostimul
observ
histolog
damag
alveolar
architectur
lung
follow
pcntreatment
regimen
lack
lung
damag
associ
pcn
treatment
support
absenc
increas
level
serum
albumin
figur
lactat
dehydrogenas
figur
recov
balf
mice
time
absenc
weight
loss
pcn
treatment
regimen
data
shown
howev
sinc
alreadi
demonstr
novel
small
agent
act
immunostimulatori
role
lung
enhanc
protect
innat
immun
respons
bacteri
pathogen
could
detect
immunogen
chang
lung
follow
pcn
treatment
regimen
examin
potenti
pcn
treatment
regimen
enhanc
protect
rang
pulmonari
bacteri
pathogen
three
day
conclus
pcn
treatment
regimen
mice
receiv
pulmonari
challeng
colonyform
unit
phase
variant
coxiella
burnetii
although
pcntreat
mice
experi
level
weight
loss
observ
pbscontrol
treat
mice
day
follow
infect
figur
differ
rate
clearanc
c
burnetii
infect
observ
pbscontrol
pcntreatment
group
figur
also
test
pcn
treatment
strategi
similar
fashion
use
francisella
tularemia
yersinia
pesti
infect
model
found
enhanc
protect
associ
pcn
treatment
data
shown
thu
pulmonari
immun
environ
elicit
pcn
treatment
regimen
seem
uniqu
suit
enhanc
resolut
subsequ
primari
viral
infect
subsequ
bacteri
infect
lung
sinc
pcn
express
purifi
e
coli
heterolog
express
system
like
contain
residu
contamin
lp
investig
potenti
adjuvantlik
role
lp
pcnenhanc
protect
treat
hej
mice
decreas
respons
lp
pcn
pb
challeng
pvm
figur
c
influenza
viru
figur
b
c
mice
treat
pcn
exhibit
significantli
reduc
influenza
viral
burden
figur
less
morbid
follow
influenza
viru
figur
b
pvm
figur
c
infect
significantli
enhanc
surviv
rate
follow
pvm
infect
figur
rel
pbstreat
control
furthermor
dramat
reduc
lp
pcn
prepar
ngdose
significantli
alter
acceler
rate
viral
clearanc
mice
treat
prepar
figur
final
treatment
hfn
protein
cage
also
produc
e
coli
presum
similar
level
lp
contamin
enhanc
protect
influenza
infect
well
treatment
pcn
prepar
figur
taken
togeth
data
strongli
suggest
presenc
lp
major
contributor
enhanc
protect
small
heatshock
pcn
intrins
immunomodulatori
appear
influenzaspecif
serum
igg
balf
igg
balf
iga
respons
acceler
significantli
greater
pcntreat
mice
follow
influenza
viru
infect
tabl
total
differenti
cell
count
recov
balf
follow
pcntreatment
regimen
prior
infect
figur
lead
specul
acceler
influenzaspecif
antibodi
respons
critic
compon
underli
protect
mechan
acceler
resolut
infect
pcntreat
mice
determin
necess
humor
immun
respons
pcnenhanc
protect
b
celldefici
umt
mice
treat
either
pcn
pb
prior
infect
influenza
viru
observ
acceler
viral
clearanc
pcntreat
wild
type
mice
pcntreat
umt
mice
figur
demonstr
requir
b
cell
enhanc
clearanc
howev
pcntreat
umt
wild
type
mice
actual
gain
weight
infect
wherea
pbstreat
umt
wild
type
mice
lost
weight
figur
indic
protect
effect
pcn
treatment
bodi
weight
loss
wholli
depend
presenc
b
cell
thu
pcninduc
mechan
respons
acceler
viral
clearanc
may
distinct
respons
decreas
weight
loss
also
observ
cell
accumul
rapidli
lung
pcntreat
mice
follow
infect
figur
lung
pbstreat
mice
determin
whether
cell
play
role
pcnmediat
protect
influenza
viru
deplet
cell
subset
prior
infect
acceler
viral
clearanc
still
observ
pcntreat
mice
deplet
cell
pcntreat
mice
deplet
cell
cell
figur
thu
cell
play
signific
role
enhanc
protect
influenza
infect
pcntreat
mice
wherea
b
cell
cell
critic
full
protect
previou
studi
indic
exist
ibalt
lung
transient
determin
durat
enhanc
protect
induc
pcn
treatment
pbsand
pcntreat
mice
challeng
influenza
viru
day
complet
pcn
treatment
although
protect
effect
pcn
treatment
wane
interv
administr
last
pcn
dose
influenza
infect
increas
viral
burden
pcntreat
mice
infect
day
last
treatment
still
significantli
reduc
rel
pbstreat
control
mice
figur
howev
protect
weight
loss
endur
figur
suggest
pcninduc
mechan
respons
acceler
viral
clearanc
may
distinct
respons
decreas
weight
loss
order
determin
whether
pcninduc
ibalt
structur
could
exclus
provid
enhanc
protect
gener
chimer
mice
reconstitut
splenectom
irradi
wild
type
lymphotoxina
lta
defici
mice
wild
type
lymphotoxina
knockout
ltako
bone
marrow
cell
bmc
use
chimer
mice
abl
effect
isol
ibalt
gener
immun
gener
convent
secondari
lymphat
tissu
follow
type
bone
marrow
chimer
mice
made
chimera
lack
secondari
lymph
node
ln
peyer
patch
could
still
form
organ
ibalt
lta
defici
mice
receiv
wild
type
bmc
slp
chimer
mice
chimera
lack
ln
peyer
patch
unabl
form
organ
ibalt
due
lack
lta
lta
defici
mice
receiv
lta
defici
bmc
ltako
chimer
mice
chimera
retain
ln
peyer
patch
likewis
unabl
form
organ
ibalt
due
lack
lta
wild
type
mice
receiv
lta
defici
bmc
wtlta
chimer
mice
wild
type
control
chimera
retain
ln
peyer
patch
could
form
organ
ibalt
wild
type
mice
receiv
wild
type
bmcwild
type
chimer
mice
follow
engraft
transfer
bmc
chimera
treat
pcn
pb
challeng
influenza
viru
day
last
treatment
seven
day
infect
pcntreat
wild
type
chimer
mice
fill
squar
slp
chimer
mice
fill
circl
significantli
less
viru
lung
rel
respect
pbstreat
cohort
open
squar
open
circl
respect
figur
extent
viral
clearanc
pcntreat
wtlta
chimer
mice
fill
triangl
ltako
chimer
mice
fill
diamond
make
organ
ibalt
closer
equival
respect
pbstreat
mice
open
triangl
open
diamond
respect
howev
weight
loss
pcntreat
chimer
mice
figur
togeth
result
indic
organ
secondari
lymphoid
tissu
requir
pcninduc
enhanc
protect
influenza
viru
infect
preexist
ibalt
exclus
account
enhanc
protect
viral
infect
like
also
associ
protect
weight
loss
associ
ibalt
structur
lung
patholog
autoimmun
diseas
observ
pcn
treatment
alter
lung
microarchitectur
elicit
influx
leukocyt
enhanc
local
pulmonari
immun
ibalt
format
suggest
pcn
treatment
regimen
may
leav
lung
suscept
develop
allerg
airway
hyperrespons
assess
possibl
mice
system
sensit
ovalbumin
treat
pcn
pb
given
intranas
instil
ovalbumin
subsequ
challeng
methacholin
interestingli
airway
hyperrespons
penh
valu
attenu
pcntreat
mice
figur
eosinophil
influx
lung
reduc
figur
result
indic
pcninduc
alter
lung
render
lung
suscept
exacerb
allerg
airway
hyperrespons
result
clearli
indic
pulmonari
instil
pcn
dramat
enhanc
subsequ
host
immun
respons
primari
viral
infect
lung
well
curtail
extent
pulmonari
damag
respons
caus
absenc
damag
indic
recov
balf
serum
albumin
ldh
pcntreat
mice
infect
reduc
recoveri
infect
lack
morbid
mice
resolut
infect
suggest
pcntreatment
figur
effect
pcn
treatment
endur
elicit
ibalt
structur
exclus
resolv
influenza
infect
mice
treat
pcn
clear
bar
pb
shade
bar
rest
design
period
time
challeng
influenza
viru
assess
viral
clearanc
carri
plaqu
assay
dot
line
limit
assay
detect
b
weight
chang
pcntreat
mice
close
symbol
pbstreat
control
mice
open
symbol
monitor
week
follow
influenza
viru
challeng
influenza
viru
challeng
given
day
squar
symbol
day
triangl
symbol
day
circl
symbol
day
diamond
symbol
conclus
pcn
treatment
regimen
rel
correspond
pbstreat
control
c
splenectomizedirradi
mice
reconstitut
bmc
order
make
chimer
mice
respond
ibalt
structur
could
isol
convent
secondari
lymphoid
tissu
wild
type
chimer
mice
wild
type
mice
receiv
wild
type
bmc
squar
symbol
wtlta
chimer
mice
wild
type
mice
receiv
lta
ko
bmc
triangl
symbol
slp
chimer
mice
lta
ko
mice
receiv
wild
type
bmc
circl
symbol
lta
ko
chimer
mice
lta
ko
mice
receiv
lta
ko
bmc
diamond
symbol
follow
engraft
transfer
bmc
group
chimer
mice
treat
pcn
solid
symbol
pb
open
symbol
challeng
influenza
viru
viral
burden
determin
day
infect
p
dot
line
limit
assay
detect
chang
bodi
weight
rel
time
viral
challeng
monitor
daili
pcn
pbstreat
chimer
mice
symbol
design
figur
rel
correspond
pb
control
induc
inflammatori
damag
lung
even
though
pcn
treatment
alter
pulmonari
microarchitectur
induc
ibalt
structur
abl
elicit
influx
leukocyt
airway
chang
immun
environ
lung
appar
consequ
well
mice
fact
result
suggest
pcntreatment
prior
infect
associ
amelior
often
excess
inflammatori
respons
seen
resolut
pulmonari
viral
infect
well
airway
hyperrespons
inflamm
associ
asthma
interestingli
alter
immun
environ
lung
respons
pcn
treatment
effect
upon
resolut
pulmonari
bacteri
infect
immunomodulatori
effect
elicit
pcntreatment
depend
b
cell
cell
either
cell
convent
secondari
lymphoid
tissu
spleen
lymph
node
peyer
patch
result
strongli
suggest
immunomodulatori
effect
mediat
signific
degre
asymptomat
induct
ibalt
lung
recipi
mice
consist
previou
result
show
pulmonari
immun
respons
presenc
ibalt
effici
less
damag
host
ibalt
serv
function
lymphoid
tissu
site
infect
like
acquir
antigen
quickli
respond
inflammatori
signal
lung
rapidli
therebi
facilit
acceler
local
adapt
immun
respons
given
antibodi
extraordinarili
power
neutral
viru
prevent
infect
clear
antigen
even
dampen
inflamm
via
fcr
ligat
acceler
igg
iga
respons
lung
like
contribut
least
partial
enhanc
viral
clearanc
pcntreat
mice
adapt
immun
probabl
compon
immun
system
affect
pcntreatment
sinc
protect
sarscoronaviru
infect
alreadi
appar
day
infect
well
adapt
primari
immun
respons
expand
point
effect
thu
like
innat
mechan
also
modul
pcn
treatment
pcn
treatment
may
enhanc
innat
antivir
mechan
current
unknown
data
suggest
like
involv
b
cell
andor
celldepend
mechan
believ
induct
ibalt
respons
treatment
pcn
repres
promis
strategi
pulmonari
immunoprophylaxi
prophylact
strategi
could
enhanc
primari
immun
respons
spectrum
respiratori
virus
make
respons
effici
clear
viru
also
less
damag
lung
process
abil
nonspecif
enhanc
immun
protect
divers
respiratori
virus
notabl
absenc
signific
pulmonari
inflamm
underscor
potenti
effect
strategi
infect
antigen
variant
current
circul
virus
swine
influenza
pandem
newli
emerg
virus
sar
epidem
numer
common
respiratori
virus
specif
vaccin
yet
success
develop
rsv
vaccin
male
femal
wild
type
balbc
mmt
tmlcgn
mice
bred
montana
state
univers
bozeman
mt
lpsd
male
femal
mice
purchas
jackson
laboratori
bar
harbor
usa
b
boyaitac
mice
express
congen
maker
purchas
tacon
laboratori
hudson
ny
usa
bonemarrow
chimer
mice
gener
splenectomizedirradi
recipi
mice
describ
influenza
viru
strain
obtain
trudeau
institut
saranac
lake
ny
usa
pneumoviru
mice
pvm
gift
dr
helen
rosenberg
niaid
nih
bethesda
md
usa
work
murin
adapt
sarscov
carri
dr
dale
barnard
utah
state
univers
logan
ut
usa
studi
describ
approv
iacuc
board
montana
state
univers
utah
state
univers
prior
perform
chimer
mice
gener
bone
marrow
reconstitut
irradi
lymphotoxina
knockout
lta
ko
mice
splenectom
week
earlier
splenectom
recipi
mice
gamma
irradi
dose
rad
administ
h
apart
recipi
mice
immedi
reconstitut
intraven
tail
inject
congen
donor
bone
marrow
cell
bmc
anim
rest
week
allow
establish
engraft
bone
marrow
cell
discrep
marker
donor
recipi
mice
use
monitor
engraft
donor
bmc
whenev
possibl
follow
chimer
mice
made
wild
type
bmc
wild
type
mice
wild
type
bmc
lta
ko
mice
lta
ko
bmc
wild
type
mice
lta
ko
bmc
lta
ko
mice
genom
dna
methanococcu
jannaschii
obtain
atcc
clone
character
purif
small
heatshock
protein
shsp
archaeon
carri
e
coli
express
vector
describ
previous
purifi
pcn
store
use
administr
pcn
viral
infect
carri
mice
light
anesthesia
use
isofluran
inhal
pcn
inocul
contain
mg
per
dose
influenza
inoculum
contain
pfu
inoculum
contain
pfu
pvm
inocul
dilut
viral
stock
sarscov
infect
carri
use
viral
stock
coxiella
burnetii
infect
carri
use
genom
equival
phase
variant
daili
bodi
weight
mice
monitor
follow
infect
design
time
follow
viral
infect
mice
sacrif
intraperiton
administr
lethal
dose
sodium
pentobarbit
mgkg
follow
exsanguin
mice
longer
exhibit
pedal
reflex
lung
harvest
snapfrozen
liquid
nitrogen
store
futur
use
viral
plaqu
assay
recoveri
bacteri
genom
copi
lung
use
immunohistolog
stain
instil
oct
tissu
tek
sakura
finetek
usa
inc
torranc
ca
usa
snap
frozen
liquid
nitrogen
store
futur
use
lung
section
cut
stain
fitcconjug
antimous
peconjug
antimous
peconjug
antimous
bd
bioscienc
san
diego
ca
usa
bronchoalveolar
lavag
fluid
balf
obtain
wash
lung
ml
mm
edta
hbss
two
aliquot
ml
cell
recov
balf
count
spun
recov
balf
recov
fluid
store
futur
use
determin
level
serum
albumin
lactat
dehydrogenas
influenzaspecif
antibodi
serum
albumin
content
balf
determin
use
albumin
colorimetr
assay
sigmaaldrich
st
loui
mo
usa
color
absorb
read
nm
report
mg
ml
balf
level
ldh
detect
balf
determin
colorimetr
assay
cytotox
promega
madison
wi
usa
assay
absorb
read
nm
report
uml
balf
sampl
test
duplic
deplet
cell
subset
accomplish
intraperiton
inject
specif
monoclon
antibodi
mab
cell
deplet
inject
ug
antimous
mab
cell
deplet
similar
manner
use
antimous
mab
tib
inject
monoclon
antibodi
given
hour
prior
infect
day
infect
use
method
deplet
select
cell
subset
endur
durat
experi
mab
made
hous
use
vitro
tissu
cultur
determin
antibodi
level
serum
balf
carri
describ
previous
briefli
ul
aliquot
dilut
serum
ul
aliquot
balf
ad
high
bind
polystyren
elisa
plate
alreadi
coat
influenza
viral
membran
prepar
subsequ
block
nonfat
skim
milk
plate
allow
incub
h
follow
wash
pbstween
ul
secondari
alkalin
phosphataseconjug
antimous
isotypespecif
antibodi
southern
biotechnolog
associ
birmingham
ab
ad
plate
allow
incub
h
presenc
bound
ab
detect
addit
pnitrophenyl
phosphat
diethanolamin
buffer
visual
nm
previous
describ
plaqu
assay
procedur
use
experi
report
briefli
serial
dilut
lung
homogen
use
inocul
confluent
monolay
madindarbi
canin
kidney
cell
follow
inocul
procedur
assay
allow
incub
day
prior
fix
acet
acid
stain
crystal
violet
reveal
presenc
viral
plaqu
balbc
mice
sensit
ovalbumin
ova
intraperiton
inject
ug
mg
alum
adjuv
rest
day
receiv
intranas
ug
pcn
instil
week
period
five
day
last
intranas
pcn
instil
mice
given
intranas
challeng
ug
ova
pb
consecut
day
follow
day
penh
valu
estim
airway
hyperrespons
methacholin
dose
respons
challeng
monitor
use
buxco
whole
bodi
plethysmograph
figur
pcninduc
enhanc
resolut
subsequ
influenza
viru
infect
reduc
size
pcn
dose
diminish
mice
treat
design
dose
pcn
pb
ug
pcn
via
intranas
instil
day
three
day
last
treatment
mice
infect
pfu
strain
influenza
viru
viral
recoveri
determin
day
infect
plaqu
assay
dot
line
limit
assay
detect
rel
pb
group
ug
pcn
b
daili
percentag
weight
chang
initi
bodi
weight
time
infect
determin
vs
ug
pcn
vs
ug
pcn
vs
ug
pcn
n
mice
per
group
treatment
mice
bovin
serum
albumin
human
hchain
ferritin
cage
prior
viral
challeng
elicit
equival
enhanc
resolut
subsequ
influenza
infect
seen
pcntreat
mice
rel
pbstreat
mice
dot
line
limit
detect
assay
b
mice
treat
pcn
prior
viral
challeng
lose
bodi
weight
resolut
infect
wherea
mice
receiv
altern
treatment
lose
bodi
weight
found
mb
tif
figur
resolut
influenza
viru
infect
mice
treat
pcn
prior
challeng
treatment
mice
pcn
result
acceler
rate
viral
clearanc
rel
pbstreat
control
determin
viral
burden
lung
mice
day
postinfect
dot
line
limit
assay
detect
b
c
loss
bodi
weight
resolut
infect
significantli
less
mice
receiv
pcn
treatment
prior
infect
rel
pb
treat
control
group
viral
recoveri
day
postinfect
lung
mice
treat
pcn
contain
reduc
endotoxin
level
ngdose
p
dot
line
limit
assay
detect
found
mb
tif
figur
treatment
pcn
amelior
methacholineinduc
airway
hyperrespons
ovalbumin
sensit
mice
mice
sensit
ovalbumin
intraperiton
inject
follow
week
later
intranas
instil
ovalbumin
consecut
day
day
intraperiton
ovalbumin
inject
mice
treat
pcn
pbscontrol
everi
day
day
last
intranas
ovalbumin
instil
mice
subject
methacholin
challeng
measur
airway
hyperrespons
taken
airway
hyperrespons
penh
valu
ovalbumin
sensit
pcntreat
solid
squar
pbstreat
open
squar
mice
nonovalbumin
sensit
pbstreat
mice
open
triangl
respons
methacholin
challeng
dose
record
penh
valu
dose
greater
mgml
methacholin
taken
pbstreat
ovalbumin
mice
due
sever
airway
hyperrespons
reaction
b
eosinophil
influx
airway
calcul
differenti
cell
count
recov
balf
found
mb
tif
